Lipella Pharmaceuticals Inc. (LIPO)

Market Cap	10.98M
Revenue (ttm)	269,055
Net Income (ttm)	-2.93M
Shares Out	5.74M
EPS (ttm)	-0.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,040
Open	1.94
Previous Close	1.94
Day's Range	1.88 - 2.00
52-Week Range	1.69 - 7.72
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 15, 2023

About LIPO

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 20, 2022
• Employees: 5
• Stock Exchange: NASDAQ
• Ticker Symbol: LIPO

Financial Performance

In 2022, LIPO's revenue was $184,156, a decrease of -28.99% compared to the previous year's $259,347. Losses were -$2.60 million, 39.3% more than in 2021.